# FDA 483 - Jeffrey W. Taub, M.D. - October 12, 2022

Source: https://www.keypedia.com/records/483/jeffrey-w-taub-md/503004c8-f98b-4eac-bf4e-97cc5e941ed2

> FDA 483 for Jeffrey W. Taub, M.D. on October 12, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Jeffrey W. Taub, M.D.
- Inspection Date: 2022-10-12
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations III
- Summary: Jeffrey W. Taub, MD, Clinical Investigator, in Detroit, MI, was cited for significant issues during an FDA inspection. The investigation was not conducted according to the investigational plan, specifically regarding failures in the informed consent process and a participant receiving unauthorized additional study treatment. Additionally, there were failures to ensure IRB compliance, leading to lapses in study approval for multiple protocols.

## Related Officers

- [issuing_officer](https://www.keypedia.com/people/jennifer-a-kemp/51aa8f2f-ba64-47d3-aa06-b4595b3d15c8)
- [Andrace Deyampert](https://www.keypedia.com/people/andrace-deyampert/cdb4f833-488b-42b9-abab-4216435bce4c)

Company: https://www.keypedia.com/companies/jeffrey-w-taub-md/0b80b258-3013-432f-b99a-15b9d7ce8214

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iii/45bc2d0d-d731-4955-aeb5-59aa0b76e4f0